KRED

Wednesday, May 17, 2017

Coherus BioSciences Prevails in ‘135 IPR Decision

http://ift.tt/eA8V8J

REDWOOD CITY, Calif., May 16, 2017 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that the Patent Trial and Appeal Board (“PTAB”) of the U.S. Patent and Trademark Office ruled in favor of Coherus’ petitions for Inter Partes Review (“IPR”) of AbbVie’s U.S. Patent 8,889,135 (the ‘135 Patent).  The PTAB’s decision invalidates all claims …

The post Coherus BioSciences Prevails in ‘135 IPR Decision appeared first on ForexTV.

May 17, 2017 at 04:34AM

http://ift.tt/2qqgaaJ

from Nasdaq NewsFeed

http://ift.tt/2qqgaaJ